Congress guarantees federal PPE purchases from domestic makers—at whatever price they set.

What it does

This bill directs the Department of Health and Human Services to create a domestic PPE manufacturing partnership program, requiring eligible U.S. manufacturers to gradually shift production to the continental U.S. (50% by 2026, 75% by 2027, 100% by 2028) in exchange for federal purchasing agreements. It also bans federal, state, and local agencies from using federal funds to buy PPE manufactured outside the U.S., with limited exceptions. The bill benefits domestic PPE manufacturers by guaranteeing federal demand and market access; ordinary citizens benefit indirectly through domestic supply resilience and potential job creation, though at potentially higher costs.

Why we flagged it

The bill's core mechanism is a protected-market arrangement: it guarantees federal demand for domestic PPE manufacturers while banning foreign procurement. This is industrial policy dressed as emergency preparedness—a subsidy-by-procurement that prioritizes domestic supply over cost efficiency.

• Section 4 requires a report on PPE-requirement changes since COVID-19 and their impact on frontline worker safety (2020–2021). Unrelated to the forward-looking domestic manufacturing program; appears to be a legislative fact-finding rider.

What the text implies

• The 'fair-market benchmarks' for PPE pricing (Section 2(d)(2)(C)) are set by the Secretary with no competitive bidding requirement, potentially allowing manufacturers to capture monopoly rents on guaranteed federal purchases.
• State and local governments are prohibited from using ANY federal funds for foreign PPE, even in emergency situations where domestic supply is unavailable or inadequate—the exceptions in 41 U.S.C. § 8302 may be narrow.
• The bill requires manufacturers to be 'majority owned and operated by United States citizens' but does not define 'operated by'—foreign nationals in management roles may be permitted, creating a loophole.
• Guaranteed federal purchasing agreements create a de facto subsidy: manufacturers receive revenue certainty without competitive pressure, potentially reducing innovation incentives and allowing cost-plus pricing.
• The domestic-production ramp (50%→75%→100% by 2028) is mandatory but the bill contains no enforcement mechanism or penalty for non-compliance, making the timeline aspirational rather than binding.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens gain supply-chain resilience and domestic manufacturing jobs, but the bill's procurement restrictions and guaranteed-purchase mechanism may increase PPE costs for federal, state, and local agencies—costs ultimately borne by taxpayers. The domestic-production mandate creates a protected market that benefits manufacturers more directly than the general public.

Who stands to gain

• domestic PPE manufacturers (guaranteed federal purchasing agreements)
• U.S.-based medical device and protective equipment suppliers
• domestic textile and manufacturing facilities (production ramp-up)

Named in the bill

Department of Health and Human Services (HHS), Assistant Secretary for Preparedness and Response (ASPR), Centers for Disease Control and Prevention (CDC), Department of Defense (DoD), Department of Homeland Security (DHS), Occupational Safety and Health Administration (OSHA), Federal Food, Drug, and Cosmetic Act (Section 510(k)), Public Health Service Act (Section 319), 41 U.S.C. § 8302 (Buy American Act)

Where it stands

• Jan 23, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jan 23, 2025 — Referred to House Committee on Oversight and Government Reform and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Oversight and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.